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ABSTRACT

Ovarian cancer has the highest mortality rate among all gynecological
malignancies due to lack of effective biomarkers for early diagnosis. The majority of
ovarian cancer patients are already at an advanced stage when diagnosed. In addition,
ovarian cancers often become chemoresistant and metastatic, and recur following initial
chemotherapy.
Eukaryotic initiation factor 5A2 (EIF5A2) is an isoform of eukaryotic initiation
factor (EIF5A). EIF5A2 is involved in protein translation, elongation, and termination.
EIF5A2 is rarely detected in normal tissues but is highly expressed in many malignancies
including ovarian cancer. EIF5A2 expression is highly correlated with poor patient
survival. However, the functions of EIF5A2 and the underlying molecular mechanisms
that contribute to ovarian tumor development have not been well investigated. The goal
of this study was to determine the regulatory mechanisms of EIF5A2 expression in
ovarian cancer and define the role of EIF5A2 in ovarian primary tumor growth and
metastasis.
In this study, we found that CRISPR/Cas9 mediated knockout (KO) of EIF5A2
inhibits the epithelial to mesenchymal transition (EMT) in ovarian cancer cells and
suppresses cell migration and invasion. In contrast overexpression of EIF5A2 promotes
EMT, migration, and invasion. Moreover, KO of EIF5A2 inhibits primary ovarian tumor
growth and metastasis in an orthotopic ovarian cancer mouse model. KO of EIF5A2
attenuates the TGFβ signaling pathway, and TGFβ induces EIF5A2 expression through
transcriptional regulation in ovarian cancer cells. Our findings demonstrated that EIF5A2
promotes EMT via activating the TGF pathway in ovarian cancer cells, and EIF5A2
forms a positive feedback loop with TGFβ and contributes to ovarian tumor metastasis by
promoting EMT.
EIF5A is the only known hypusinated protein, and hypusination is required for
EIF5A2 maturation. The amino acid hypusine is formed by the post-translational
modification of lysine 50 residue in the EIF5A2 molecule through deoxyhypusine
synthase (DHS). N1-guanyl-1, 7-diaminoheptane (GC7), an inhibitor of DHS, blocks the
hypusination of EIF5A2. Disruption of the EIF5A2-hypusination pathway, by either
genetic or pharmacological approaches, suppresses ovarian tumor growth and metastasis.
In summary, this study addressed the molecular mechanisms involved in the
regulation of EIF5A2 in ovarian tumor metastasis and identified novel therapeutic
strategies to combat ovarian cancer by targeting EIF5A2/TGF/EMT axis or
hypusination pathways.
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CHAPTER 1.

INTRODUCTION

Background
Ovarian cancer ranks fifth in causing death among women’s malignancies. Over
300,000 ovarian cancer cases were diagnosed globally in 2018, and it is projected that by
the year of 2035 the case number will rise to 371,000 per year and deaths of 254,000 per
year (Bhatla and Jones, 2018). The five-year survival rate of ovarian cancer is
approximately 47%, which is the lowest survival among gynecological malignances
(Torre et al. 2018). The high mortality rate of ovarian cancer patients reflects the
typically late stage of the cancer at time of diagnosis. More than three quarters of ovarian
cancer patients are diagnosed at stages III and IV, when cancer cells already have spread
throughout the abdominal cavity. Therefore, it is essential to identify novel biomarkers
for early diagnosis and develop therapeutics to inhibit ovarian tumor metastasis (Brown
and Palmer, 2009; Burger, 2008; Kurman et al., 2008).
Ovarian carcinoma metastasis is markedly different from other types of cancer.
While the classic and well-studied hematogenous metastasis is the major approach for
other cancers, ovarian carcinoma disseminates through pelvic or para-aortic lymph nodes
and directly invades neighboring or distant organs, including omentum, colon and liver.
This process allows ovarian tumor cells to spread easier than other carcinomas (Eisenkop
and Spirtos, 2001).

Ovarian cancer development
Based on tumor cell morphology, ovarian cancer is classified into two categories:
non-epithelial and epithelial ovarian cancer (EOC) (Bast et al., 2009). The majority of
ovarian tumors belong to EOC, which accounts for 95% of the ovarian malignancies. The
effective detection of early-stage EOC requires the understanding of the mechanisms of
EOC initiation, progression, and metastatic transition (Kim et al., 2018).
EOCs were thought to originate from ovarian surface epithelial (OSE) cells
(Hamilton, 1992). In the past two decades, the fallopian tube epithelium (FTE) has
emerged as the new primary origin of EOC (Kindelberger et al., 2007; Nik et al., 2014).
However, recent studies indicated that both OSE and FTE are the origins of epithelial
ovarian cancer (Kim et al., 2018).
During initial tumor metastasis, EOC cells detach from ovaries and dissociate into
single cells or form tumor spheres in the peritoneal cavity (Lengyel, 2010). While single
tumor cells undergo apoptosis, the tumor spheres metastasize to distant organs,
accompanied by frequent ascitic fluid accumulation, which contributes to a poor patient
survival rate (Lengyel, 2010; Scalici et al., 2017; Ahmed and Stenvers, 2013).
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Epithelial-to-mesenchymal transition (EMT). EMT is characterized by the loss
of adherence junctions and apical-basal polarity, gain of motility, and switch into stem
cell-like mesenchymal phenotype (Nieto, 2013). EMT has been found to participate in
many biological processes, such as epithelial development, wound healing, organ
fibrosis, and cancer metastasis (Nieto et al., 2016; Nauseef and Henry, 2011; Micalizzi et
al., 2010). Experimental evidence demonstrates that EMT is essential in tumor initiation,
progression, invasion and metastasis (Micalizzi et al., 2010; Drasin et al., 2011; DiMeo et
al., 2009).
The role of EMT in ovarian cancer supports its participation in metastasis and
chemoresistance (Lili et al., 2013; Ahmed et al., 2010). For example, EMT contributes to
ovarian cancer cell survival in low oxygen conditions, and the secretion by tumor cells of
soluble factors that regulate the function of surrounding stromal cells (Imai et al., 2003).
Prior to their detachment and metastasis, ovarian carcinoma cells often undergo EMT,
which reduces the intercellular adhesion between cancer cells and facilitates the
attachment of epithelial cells to the basement membrane (Figure 1-1) (Farghaly, 2012).
Once the ovarian tumor cells establish a metastatic colony in the omentum or peritoneum,
tumor cells undergo the mesenchymal-to-epithelial transition (inverse of the process of
EMT) to regain an epithelial phenotype, which permits cells to interact with paracrine
growth factors and proliferate at a high growth rate (Haque and Morris, 2017).
The phenotypic switch in EMT is accompanied by alternating the gene expression
profiles of both epithelial and mesenchymal markers, such as Ecadherin, Snail1 and
Snail2, Twist, Vimentin, ZEB1, ZEB2, and others (Zhao et al., 2019). In epithelial
cancer, the acquisition of an invasive phenotype during EMT typically correlates with the
loss of Ecadherin (Kalluri and Weinberg, 2009). Ovarian tumor cells in ascites and at
metastatic sites have lower Ecadherin expression than primary tumor cells, and ovarian
carcinoma with lower Ecadherin is more invasive and associated with poor patient
survival (Daraï et al., 1997). Furthermore, EMT is regulated by multiple signaling
pathways including TGFβ, WNT, and Notch, which are activated in various human
cancers (DiMeo et al., 2009; Miyamoto et al., 2013; Liu et al., 2012b; Hoffmeyer et al.,
2012; Espinoza et al., 2013; Muraoka et al., 2002).
Despite the significant improvement in understanding the molecular mechanisms
of EMT in the past decade, it is still unclear how EMT is regulated in ovarian tumor
progression and metastasis. It is important to further identify the critical target genes or
gene networks in regulating EMT and develop the novel therapy by reversing the EMT
phenotypic switch.
Transforming growth factor- (TGF). TGF is a multifunctional cytokine that
regulates many biological processes, including cell growth, differentiation, apoptosis, and
motility as well as extracellular matrix production, angiogenesis, and cellular immunity
(Haque and Morris, 2017). The role of TGF in cancer development is paradoxical:
TGF can inhibit cellular transformation and block cancer progression when cancer
development is in the early stages; however, in later stages cancer cells can circumvent
the inhibitory effects of TGF and undergo tumor progression by promoting EMT,
2

Figure 1-1. Scheme showing a working model of ovarian cancer progression.
There are three stages during ovarian tumor metastasis. In stage 1, epithelial ovarian
tumor cells undergo EMT to obtain motility and start to metastasize. The shed tumor cells
undergo apoptosis while the other surviving tumor cells form cellular aggregates or
spheroids during stage 2. The cellular aggregates and spheroids subsequently infiltrate the
mesothelial lining of the abdominal cavity where they undergo MET to allow cells to
attach and proliferate and migrate.
Reprinted with open access permission. Farghaly, S. (2013). “Anti-metastatic gene
therapy in patients with advanced epithelial ovarian cancer (EOC).” J Cell Sci Ther, S:15,
2.
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stimulating angiogenesis, and inducing immunosuppression (Yan and Sun, 2014; Haque
and Morris, 2017).
TGF effectively induces EMT in various epithelial cells (Xu et al., 2009). TGF
causes the phenotypic switch from cuboidal epithelial cells into elongated spindle
mesenchymal cells, which is accompanied by reduced expression of epithelial markers
and increased expression of mesenchymal markers (Miettinen et al., 1994). Enhanced
production of active TGFβ is often observed in cancer cells. A study showed that the
conversion into more invasive spindle cell carcinomas correlates with the expression of
activated TGFβ (Cui et al., 1996). Enhanced TGFβ production not only triggers EMT and
enables cellular invasiveness but also promotes angiogenesis in the tumor
microenvironment, offering an exit route for migratory mesenchymal cells (Derynck et
al., 2001).
In the TGF signaling pathway, TGF binds to transforming growth factor-
receptor-2 (TGFR2) and initiates the signaling process. The binding process also
requires transforming growth factor- receptor-3 (TGFR3, also known as -glycan),
which induces a conformational change in TGFR2 that facilitates the ligand-receptor
binding (López-Casillas et al., 1993; Sankar et al., 1995). TGF receptor-1
(TGFR1)/ALK-5, a serine/threonine kinase, is incorporated into the TGF/TGFR2
complex to phosphorylate Smad2 and Smad3 and initiate signaling. Smad2 and Smad3
are two proteins belonging to the receptor-regulated Smad family (Haque and Morris,
2017). The phosphorylated Smad2 and Smad3 combine with Smad4 to form the
heteromeric Smad complex, which then translocates into the cell nucleus and interacts
with various transcriptional factors to activate downstream target genes (Dou et al.,
2000).
The eukaryotic initiation factor 5A (EIF5A). EIF5A is present in most of the
eukaryotic cells (Park et al., 1993) and was initially identified as a translation initiation
factor that acts in the final step of protein synthesis by promoting the formation of the
first peptide bond (Wu et al., 2020). Recent experimental results have suggested that
EIF5A also participates in translation elongation and termination (Wu et al., 2020). A
positive correlation has been found between cancer cell proliferation and EIF5A
expression during protein synthesis (Caraglia et al., 2013). Mounting evidence indicates
that EIF5A promotes cell proliferation, cancer progression, invasiveness and metastasis,
and is also associated with poor clinical prognosis (Caraglia et al., 2013; Xie et al., 2008;
Lee et al., 2010; Marchet et al., 2007; Clement et al., 2006).
There are two isoforms of EIF5A, EIF5A1 and EIF5A2, which have 84%
similarity in cDNA and 94% similarity in protein sequences (Clement et al., 2003; Saini
et al., 2009). EIF5A1 is expressed in many normal tissues while EIF5A2 is expressed
only in specific normal tissues. However, both EIF5A1 and EIF5A2 expression is
elevated in a variety of cancers. The low expression of EIF5A2 in normal tissues and
high expression in cancer tissues makes EIF5A2 a potentially more sensitive biomarker
for cancer diagnosis than EIF5A1.
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EIF5A2 is located near chromosome 3q26, which is frequently amplified in many
solid tumors (Wang et al., 2013). Overexpression of EIF5A2 is associated with a more
advanced and aggressive disease status in many cancers. For example, one study found
that EIF5A2 expression correlates with tumor recurrence and progression in pTa/pT1
urothelial carcinoma of the bladder (Luo et al., 2009). Silencing EIF5A2 in ovarian
cancer cell line UACC-1598 inhibits cell growth and blocks the oncogenic properties of
EIF5A2 (Clement et al., 2006). EIF5A2 expression is also significantly correlated with
tumor cell proliferation in colorectal cancer (Xie et al., 2008). In addition, a higher risk of
lymph node metastasis is strongly associated with expression of EIF5A2 in colorectal
carcinoma (Xie et al., 2008; Lee et al., 2010; Marchet et al., 2007). In gastric cancer,
EIF5A2 is correlated with advanced clinic pathological features and reduced survival. In
hepatocellular carcinoma (HCC), more than half of HCC show upregulated mRNA levels
of EIF5A2 compared to normal tissues. By Kaplan–Meier analysis, EIF5A2 expression is
significantly associated with shorter survival of HCC patients (Cao et al., 2017). The
expression level of EIF5A2 is high in many non-small cell lung cancers and low in all
tested normal lung tissue (He et al., 2011). In cervical cancer tissues, the levels of both
EIF5A2 mRNA and protein are upregulated compared to adjacent non-tumor tissues, and
the aggressive features of cervical cancer is associated with higher EIF5A2 expression
(Yang et al., 2016b). EIF5A2 is also suggested to be a potential biomarker for shorter
overall survival and disease-free survival in stage II cervical cancer patients as well as in
patients with a negative pelvic lymph node status. In esophageal squamous cell
carcinoma (ESCC), tumor tissues show elevated levels of EIF5A2 mRNA compared with
paired non-tumor tissues, and tumor tissues have higher frequency of positive staining of
EIF5A2 than in non-tumor tissues based on immunohistochemistry staining of 232 tumor
tissues and 215 non-tumor tissues (Li et al., 2014). The authors also revealed that EIF5A2
contributes to metastasis and angiogenesis in ESCC, suggesting that EIF5A2 is a
promising target for treatment. Overexpression of EIF5A2 in various types of human
cancers are summarized in Table 1-1.
A previous study suggested that EIF5A2 is an important biomarker for the
prognosis of many human cancers (Wang et al., 2013). Knockdown of EIF5A2
effectively suppresses tumor cell growth and migration, suggesting that EIF5A2 has
potential as target for anticancer therapy (Wang et al., 2013). However, the molecular
mechanisms underlying the regulation of EIF5A2 expression remain unknown. One study
suggested that EIF5A2 shuttles between cell nucleus and cytoplasm (Zender et al., 2008).
Experimental evidence supporting EIF5A2 as a transcriptional factor in the nucleus is
still lacking. How is EIF5A2 frequently overexpressed in various human cancers? What
are the upstream and downstream targets of EIF5A2 in human cancers? How does
EIF5A2 regulate EMT in cancers? Those questions need to be further addressed.
EIF5A2 was first detected in ovarian cancer cell line UACC-1598 (Clement et al.,
2003). In a later study, EIF5A2 was found in 7% of cystadenomas, 30% of borderline
tumors, 53% of invasive ovarian carcinomas, and 16% of informative ovarian carcinomas
while EIF5A2 was barely detected in normal ovaries (Yang et al., 2009). EIF5A2
expression is significantly associated with shortened patient survival (mean 39.0 months
vs 69.5 months) in ovarian carcinoma (Yang et al., 2009). These findings suggest that
5

Table 1-1.

Summary of EIF5A2-overexpression-related findings in human cancers.
Main conclusions related with high level EIF5A2 in various human cancers

Reference

Overexpression of EIF5A2 in Federation of Gynecology and Obstetrics (FIGO) stage I-II cervical
cancer cells showed strong cancer progression, and patients showing high EIF5A2 expression in
tumors had relatively shorter survival time.

(Yang et al., 2016b)

Silencing of EIF5A2 inhibits cell migratory and invasive capacities in non-small cell lung cancer
(NSCLC) tissues.

(Chen et al., 2018), (He et
al., 2011)

EIF5A2 promotes melanoma cell invasion by targeting phosphorylated Akt and was inversely
correlated with the 5-year survival time of primary melanoma patients.

(Khosravi et al., 2014),
(Khosravi et al., 2016)

EIF5A2 overexpression in esophageal squamous cell carcinoma (ESSC) cells can induce
chemoresistance to chemotherapeutic drugs, enhances metastasis and angiogenesis, and is
correlated with a shorter survival times of patients.

(Yang et al., 2015), (Li et al.,
2014)

EIF5A2 affects the doxorubicin chemoresistance in breast cancer, and inhibition of EIF5A2
activation can enhance the therapeutic efficacy of doxorubicin in estrogen negative cancer cells.

(Liu et al., 2015a), (Liu et
al., 2015b)

Overexpression of EIF5A2 in colorectal carcinoma cells may help the acquirement of metastatic
phenotype and assist the cancer development and progression.

(Xie et al., 2008)

EIF5A2 is highly expressed in prostate cancer and significantly associated with poor progressionfree survival.

(Lu et al., 2019)

EIF5A2 overexpression is correlated with tumor metastasis in bladder cancer patients and promotes
aggressiveness in cancer cells.

(Wei et al., 2014), (Chen et
al., 2009), (Luo et al., 2009)

EIF5A2 can target the miR-125b and regulate the fatty acid de novo biosynthesis in hepatocellular
carcinoma (HCC) cells.

(Tsang et al., 2014), (Cao et
al., 2017),

EIF5A2 can be a novel therapeutic target for the treatment of nasopharyngeal carcinoma patients.

(Huang et al., 2016)

EIF5A2 associated with poor overall survival time in gastric cancer patients.

(Yang et al., 2016a)
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elevated EIF5A2 in ovarian carcinoma may promote the malignant phenotype. Therefore,
EIF5A2 is a potential independent biomarker of shortened survival time for ovarian
cancer patients (Yang et al., 2009). However, the precise role of EIF5A2 and its
mechanisms in ovarian cancer metastasis are still unclear.
Hypusine and deoxyhypusine. Hypusine is an uncommon amino acid, and of
human proteins only EIF5A (both EIF5A1 and EIF5A2) contains a single hypusine
residue (Caraglia et al., 2013; Maier et al., 2010). There are two reactions involved in the
hypusination of EIF5A. In the first reaction, deoxyhypusine synthase (DHS) catalytically
cleaves polyamine spermidine and transfers the 4-aminobutyl moiety to lysine 50 residue
of the EIF5A precursor to form deoxyhypusine and 1,3-diaminopropane. When the
EIF5A precursor is absent, the spermidine is catalytically cleaved by DHS and produces
1-pyrroline and 1,3-diaminopropane instead (Wolff et al., 1995), indicating that
spermidine associates with the DHS in the early stage of the catalytic reaction and does
not bind to the EIF5A protein precursor (Jakus et al., 1993). In the second reaction, a
hydroxyl group is added to the deoxyhypusine residue to form hypusine and the reaction
is mediated by deoxyhypusine hydroxylase (DOHH) (Figure 1-2) (Mathews and
Hershey, 2015; Wang et al., 2013). The hypusination of EIF5A is essential for the cell
growth and biological functions of EIF5A (Schnier et al., 1991). Thus, targeting the
hypusination potentially blocks the activity of EIF5A2 for ovarian cancer therapy.
The hypusination process can be blocked by preventing spermidine from binding
to the DHS. Thus, selective disruption of the binding between spermidine and DHS using
small molecule compounds could specifically inhibit the production of biologically active
EIF5A protein and eventually control the protein synthesis. This strategy has been
reported in many studies (Jakus et al., 1993). The inhibitory effects of several mono-, di-,
and poly-amines on DHS were also examined, and the structural features were
subsequently identified (Jakus et al., 1993). Another study reported several chemical
agents which structurally resemble spermidine and could be used as potential inhibitors to
disrupt the association between spermidine and DHS (Jakus et al., 1993). Several types of
guanidine compounds were found to be effective to inhibit DHS in cultured cells (Jakus
et al., 1993).
N1-guanyl-1,7-diamine-heptane (GC7). GC7 is one of the common inhibitors
routinely used to inhibit the DHS activity. GC7 was first synthesized in 1993 and is one
of the most competitive inhibitors for DHS (Jakus et al., 1993). GC7 fully inhibits the
hypusination at doses between 1 and 10 μM in Chinese hamster ovary cells and has the
potential for drug development and cancer therapy (Jakus et al., 1993).
Recent studies showed that GC7 inhibits tumor progression in several human
cancer cells. In breast cancer, inhibition of EIF5A hypusination with GC7 reduces
TGF/Fibronectin induced metastatic dissemination (Güth et al., 2019). In oral squamous
cell carcinoma cells, inhibition of EIF5A hypusination with GC7 achieves better antitumor effects both in vitro and in vivo when it is combined with cisplatin than cisplatin
alone (Fang et al., 2018b). In hepatocellular carcinoma cells, GC7 blocks EMT and
reverses hypoxia-induced chemotherapy resistance (Zhou et al., 2017) and inhibits
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Figure 1-2. Scheme showing the chemical reactions of hypusine formation in
EIF5A.
First, an amino-butyl moiety is transferred from the spermidine to the lysine 50 in
EIF5A2 by the enzyme deoxyhypusine synthase (DHS) and then deoxyhypusine
hydroxylase (DOHH) added a hydroxyl group to the deoxyhypusine and form the
hypusine. Data source: Maier, B., et al. (2010). “Hypusine: a new target for therapeutic
intervention in diabetic inflammation.” Discovery Medicine, 10 (50), 18-23.
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neuroblastoma (Bandino et al., 2014). GC7 also suppresses cell proliferation and induces
apoptosis in immortalized and malignant human oral keratinocytes (Lee et al., 2009).
Although GC7 demonstrates a great potential as a DHS inhibitor, its specificity is
still unclear and raises concerns about the clinical utility of GC7 for cancer treatment
(Massagué et al., 2005). Due to the high similarity between GC7 and spermidine, GC7
could potentially influence other key targets of spermidine, such as spermidine/spermine
N(1)-acetyltransferase (SAT1). SAT1 is a key regulator of the polyamine catabolism
(Pegg, 2008; Liu et al., 2012a). Therefore, the molecular modification of GC7 may be
required to improve the specificity of GC7.

Ovarian cancer treatment
Current treatment on ovarian carcinoma patients with advanced stage disease
relies on aggressive surgery, such as cytoreduction and tumor debulking to remove all
visible tumors in surgery. Cytoreduction surgery typically involves multiple surgeries to
clear as much tumor as possible in the pelvis, such as an en bloc resection of the ovarian
tumors, reproductive organs, and the sigmoid colon (Lengyel, 2010). Cytoreduction
surgery has been consistently demonstrated to improve patient survival time (Bristow et
al., 2002; Winter et al., 2007).
Drug administration by the intravenous (i.v.) and intraperitoneal (i.p.) routes is
another factor to consider and the optimal route for drug delivery is still up for debate.
Chemotherapy is typically used after surgery to kill any remaining cancer cells.
Increasing experimental evidence has showed that intraperitoneal delivery of drugs leads
to an increased progression-free survival and overall survival by several months for
patients after tumor debulking compared with patients who underwent intravenous
administration (Armstrong et al., 2006). The reason for this improvement is likely
because the ovarian tumors are confined within the peritoneal cavity and intraperitoneal
injection can achieve high concentrations of drugs in abdomen.
Due to the low number of cases compared with other diseases like breast and
colon cancers, ovarian carcinoma has had limited number of patients for large phase III
trials (Lengyel, 2010). Primary therapy is mainly cytoreductive surgery and platinumbased chemotherapy, which has been largely unchanged over the years. Other drugs to
target DNA repair, immunoregulatory pathways, and stem cell biology are also on
clinical trials for targeted gene therapy. Due to genetic similarity in primary tumors and
metastasis from other cancers, ovarian cancer can also benefit from the diagnosis and
treatment developed for other cancers. Identifying effective biomarkers for early
diagnosis of ovarian cancer can greatly help reduce mortality rate.
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Summary and Aims of Dissertation
Ovarian cancer is the most lethal gynecological cancer and most patients are
diagnosed at advanced stages. A critical barrier to progress for the treatment of ovarian
cancer is the lack of effective biomarkers for diagnosis, and the lack of mechanistic
understanding of ovarian cancer metastasis and chemoresistance. EIF5A is one of the
eukaryotic translation initiation factors and functions in both initiation and elongation of
protein synthesis. Hypusination is the key step of posttranslational modification of EIF5A
for EIF5A maturation and function. The EIF5A2 isoform of EIF5A is frequently
amplified in various solid tumors. We recently found that EIF5A2 is highly expressed in
ovarian cancer patients, and EIF5A2 expression correlates with poor patient survival. The
aim of this study is to understand the function of EIF5A2 in ovarian cancer and the
molecular mechanisms underlying tumor metastasis. We found that CRISPR/Cas9
nickase mediated EIF5A2 knockout inhibits EMT in ovarian cancer cells. We also found
that EIF5A2 and TGF signaling pathway form a positive feedback loop in ovarian
cancer cells.
Our goal was to elucidate the role of the EIF5A2/TGF/EMT axis in ovarian
cancer. The results of this study will provide novel insights on the molecular mechanisms
underlying the regulation of EIF5A2 and how the EIF5A2/TGF axis regulates EMT in
ovarian cancer. The overall goal of this work was to develop novel therapeutics for
ovarian cancer by targeting the EIF5A2/TGF axis to inhibit ovarian primary tumor
growth and metastasis.
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CHAPTER 2.

METHODS AND MATERIALS

Methods and Materials Related to EIF5A2 Enhances Ovarian Tumor Growth and
Metastasis by Promoting EMT via Activating the TGF Pathway

Cell culture
Ovarian cancer cell lines, SKOV3 and OVCAR3, were obtained from ATCC and
cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS
(Hyclone; Logan, UT), 100 U/ml penicillin/streptomycin (PS, Invitrogen; Carlsbad, CA).
OVCAR8 cell line was purchased from National Cancer Institute and cultured in RPMI
1640 with 10% FBS (Hyclone; Logan, UT), 1% penicillin/streptomycin (PS, Invitrogen;
Carlsbad, CA). Three ovarian cancer cell lines were grown using standard cell culture
techniques at 37°C under 5% carbon dioxide (CO2) and 15% oxygen (O2). Cell lines were
authenticated using Short Tandem Repeat (STR) analysis by ATCC and tested negative
for mycoplasma contamination using luciferase assay (Lonza, Allendale, NJ). Cells were
frozen at early passages and used in less than 4 weeks in continuous culture.

Lentiviral vector production
The lentiviral CRISPR/Cas9 nickase-mediated EIF5A2 gene editing vectors were
constructed by annealing two gRNA oligonucleotides and subcloning them into BsmII
site of lentiviral vector Lentiguide-puro vector (#52963, Addgene), and gRNAs were
driven by human U6 promoter. Two gRNA sequences, 5’
AACGGCTTCGTGGTGCTCAA and 5’ CGCAAGGCCGAGCACTGCAT were
designed to target exon 1 of EIF5A2 gene. The lentiviral CRISPR/Cas9 nickase-mediated
TGFβR2 gene editing vectors were constructed using the same method as we described
previously (Zhao et al., 2017) by annealing two gRNA oligonucleotides
5’TTCCAGAATAAAGTCATGGT and 5’TTCTCCAAAGTGCATTATGA to target
exon 4. EIF5A2 and EGFP lentiviral vectors were purchased from APPLIED Biological
Materials Inc. Lentivirus was produced by packaging in 293FT cells, as published
previously (Yue et al., 2010). EIF5A2 KO and TGFβR2 KD stable cell lines were
generated by transducing the ovarian cancer SKOV3 and OVCAR8 cells with the
lentiviral CRISPR/Cas9 nickase vector and selected with 2 g/ml puromycin or 10 g/ml
blasticidin. LentiCas9-blast was used as the control vector without gRNAs. EGFP control
and EIF5A2 expressing cell lines were established by transducing OVCAR3 with
EIF5A2 overexpression vector, and stable cell lines were established by selecting with 2
g/ml puromycin.
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MTT assay
SKOV3, OVCAR8 or OVCAR3 cells (3000/well) transduced with lentiviral
CRISPR/Cas9 nickase EIF5A2 gRNA and control or EIF5A2 OE and EGFP vectors were
plated into 96-well plates and cultured at different time points (24, 48 and 72 h).
Thereafter, 10 µl of MTT reagent was added to each well and incubated for ~4 h and then
terminated by adding 100 µl detergent reagent to incubate at 22°C in the dark for 2 h.
Cell proliferation was assessed by measuring the absorbance at 570 nm wavelength.

Cell clonogenic survival assay
Four hundred EIF5A2 expressing and EGFP control OVCAR3 cells, EIF5A2 KO
and control SKOV3 and OVCAR8 cells were seeded on 6-well plates and cultured for 2
weeks and then fixed with 70% ethanol and stained with crystal blue. Colonies were
counted for statistical analysis in triplicate.

Cell migration assay
The cell migration assay was assessed using a transwell chambers (BD Falcon™,
San Jose, CA) inserted into 24-well cell culture plates. SKOV3, OVCAR8 and OVCAR3
cells (5×104) in 300 µl serum-free culture medium were added into the upper chamber.
Culture medium containing 10% of FBS as the chemoattractant was added into the lower
chamber of each well and cultured for 8 h. The medium and non-migrated cells in the
upper chamber were removed, while the migrated cells on the lower side of the
membranes were fixed with methanol and stained with crystal violet. Pictures were taken
at 10X magnification, and cells from at least three different fields were counted.

Cell invasion assay
SKOV3, OVCAR3 and OVCAR8 (3×105) cells were seeded in 300 l serum-free
culture medium onto transwell plates precoated with Matrigel (BD BioSciences, San
Jose, CA). The medium containing 10% of FBS was added to the bottom chamber of the
invasion system as the chemoattractant. The transwell inserts were stained for 10 min
with hematoxylin and eosin following methanol fixation for 20 mins following overnight
incubation. Pictures were taken at 10X magnification. Invaded cells were counted from at
least three different fields.

Smad-dependent reporter gene luciferase assay
The lentiviral vector pGF-Smad2/3/4-mCMV-Luciferase-EF1a-puro (System
Biosciences, CA) containing Smad2/3/4 transcriptional response elements (TRE) was
used to transduce EIF5A2 KO and control SKOV3 and OVCAR8 cells using 10 MOI
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(multiplicity of infection). EIF5A2 KO and control cells were treated with 6 ng/ml TGFβ
for 12 h to activate Smad2/3/4 pathway. Luciferase activity was measured and
normalized by comparing to control cells.

Immunofluorescent staining
The paraffin-embedded (FFPE) blocks of fully de-identified ovarian serous
carcinoma were obtained from the Tissue Services Core of the University of Tennessee
Health Science Center (UTHSC). Hematoxylin and eosin (H&E) staining was performed
by the Histology Core of UTHSC. To detect EIF5A2 gene expression, ovarian serous
carcinoma sections were antigen-retrieved and incubated with blocking buffer (5%
normal goat serum, 3% bovine serum albumin, and 0.1% Triton-X100 in PBS) for 1 h.
The slides were incubated overnight with primary antibodies to EIF5A2, Cytokeratin-7
(1:200 dilution, Abcam, Cambridge, UK) and Vimentin (1:200 dilution, Cell Signaling,
Danvers, MA). After rinsing three times for 5 mins with PBST, Alexa 488- or 594conjugated goat anti-rabbit or –anti-mouse (Invitrogen, Carlsbad, CA) antibodies were
added and incubated for 1 h at room temperature. Cell nuclei were counterstained with
DAPI (Vector Laboratories, Inc.; Burlingame, CA). Images were captured on a Zeiss
LSM700 laser scanning confocal microscope.

Western blot
Ovarian cancer cells were collected in RIPA buffer (Thermo Scientific; Rockford,
IL) containing 1% Halt Proteinase Inhibitor Cocktail (Thermo Scientific; Rockford, IL).
An equal amount of protein (100 μg/lane) was loaded onto 10% SDS-PAGE gels and
transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat
milk for 1 h and incubated with primary antibodies against EIF5A2, Cytokeratin7(Abcam), GAPDH (Santa Cruz; St. Louis, MO), Vimentin, Ecadherin, β-catenin, snail2,
Smad2 or p-Smad2 (Cell Signaling).

Orthotopic ovarian cancer mouse model
To test the effect of EIF5A2 KO in ovarian cancer cells on ovarian tumor
metastasis, EIF5A2 KO and control SKOV3 cells were labeled with luciferase. 5×105
EIF5A2 KO and control SKOV3 cells were intrabursally injected into 10 of two-monthsold immunocompromised NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJ (NSG) female mice
(n=5/group) (#005557, Jackson Laboratory). Tumor growth and metastasis was
monitored using the Xenogen bio-imaging system once a week. Mice were sacrificed at 5
weeks after cell injection. Primary tumors from ovaries and metastatic tumors from
peritoneal organs were collected. Xenograft tumors and the peritoneal organs of each
mice were subjected to double-blind histopathologic analysis by a pathologist.
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Quantification and statistical analysis
All the statistical analysis of experimental data was carried out in Excel unless
otherwise indicated.
Western blot experiments were repeated independently for three times. The
protein bands from Western blot were quantified using the ImageJ software and GAPDH
was used as a loading control. SKOV3 and OVCAR8 cells treated with TGF for
different time points (6, 12 and 24 h) were all compared to vehicle. SKOV3 and
OVCAR8 cells treated with SB431542 in different doses (10, 20 and 40 M) were all
compared to vehicle. Statistical significance was determined by the Student’s t-test
between two groups. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
The cell survival assay and MTT were performed using three biological repeats.
The comparisons between two groups were performed using Student’s t-test.
For the migration and invasion assays, cells were counted from three different
fields using the ImageJ software. The comparisons between two groups were performed
using the Student’s t-test.
The luciferase reporter assays were performed using three biological repeats.
EIF5A2 KO with or without TGF stimulation was compared to control with or without
TGF stimulation respectively; EIF5A2- overexpression with or without TGF
stimulation was compared to control with or without TGF stimulation respectively. The
statistical comparisons between two groups were performed using Student’s t-test.

Methods and Materials Related to Disruption of Hypusination Pathway Inhibiting
Primary Ovarian Tumor Growth and Metastasis

Cell culture
Ovarian cancer cell lines, SKOV3 was obtained from ATCC and cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS (Hyclone;
Logan, UT), 100 U/ml penicillin/streptomycin (PS, Invitrogen; Carlsbad, CA). OVCAR8
cell line was purchased from National Cancer Institute and cultured in RPMI 1640 with
10% FBS (Hyclone; Logan, UT), 1% penicillin/streptomycin (PS, Invitrogen; Carlsbad,
CA). Both ovarian cancer cell lines were grown using standard cell culture techniques at
37°C under 5% carbon dioxide (CO2) and 15% oxygen(O2). Cell lines were authenticated
using Short Tandem Repeat (STR) analysis by ATCC and tested negative for
mycoplasma contamination using luciferase assay (Lonza, Allendale, NJ). Cells were
frozen at early passages and used in less than 4 weeks in continuous culture. N1-guanyl1, 7-diaminoheptane (GC7) was purchased from Millipore Sigma Inc.
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Lentiviral vector production
The lentiviral CRISPR/Cas9 nickase-mediated DHS gene editing vectors were
constructed by annealing two gRNA oligonucleotides and subcloning them into BsmII
site of lentiviral vector Lentiguide-puro vector (#52963, Addgene), and gRNAs were
driven by human U6 promoter. Two gRNA sequences,
5’AGGAAGTAGGGAACGTGCTT and 5’TTGCGGAGACGCGCGCGTCG were
designed to target exon 1 of DHS gene. Lentivirus was produced by packaging in 293FT
cells, as published previously (Yue et al., 2010). DHS KO stable cell lines was generated
by transducing the ovarian cancer SKOV3 and OVCAR8 cells with the lentiviral
CRISPR/Cas9 nickase vector and selected with 2 g/ml puromycin or 10 g/ml
blasticidin. LentiCas9-blast was used as the control vector without gRNAs.

MTT assay
SKOV3 and OVCAR8 (3000/well) transduced with lentiviral CRISPR/Cas9
nickase DHS editing and control or wildtype cells treated with GC7 were plated into 96well plates and cultured at different time points (24, 48 and 72 h). Thereafter, 10 µl of
MTT reagent was added to each well and incubated for ~4 h and then terminated by
adding 100 µl detergent reagent to incubate at 22°C in the dark for 2 h. Cell proliferation
was assessed by measuring absorbance at 570 nm wavelength.

Cell clonogenic survival assay
400 DHS KO and control SKOV3 and OVCAR8 cells or wildtype cells treated
with GC7 were seeded on 6-well plates and cultured for 2 weeks and then fixed with 70%
ethanol and stained with crystal blue. Colonies were counted for statistical analysis in
triplicate.
Cell migration assay
The cell migration assay was assessed using transwell chambers (BD Falcon™,
San Jose, CA) inserted into 24-well cell culture plates. SKOV3 and OVCAR8 cells (5 ×
104) transduced with lentiviral CRISPR/Cas9 nickase DHS editing and control or
wildtype cells treated with GC7 were seeded in 300 µl serum-free culture medium and
added to the upper chamber. Culture medium containing 10% of FBS as the
chemoattractant was added into the lower chamber of each well and cultured for 8 h. The
medium and non-migrated cells in the upper chamber were wiped away, while the
migrated cells on the lower side of the membranes were fixed with methanol and stained
with crystal violet. Pictures were taken at 10X magnification and cells were counted from
at least three different fields.
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Cell invasion assay
SKOV3 and OVCAR8 (3×105) cells transduced with lentiviral CRISPR/Cas9
nickase DHS editing and control or wildtype cells treated with GC7 were seeded in 300
l serum-free culture medium and put into transwell plates precoated with Matrigel (BD
BioSciences, San Jose, CA). The medium containing 10% of FBS was added to the
bottom chamber of the invasion system as the chemoattractant. The transwell inserts were
stained for 10 min with hematoxylin and eosin following methanol fixation for 20 mins
following overnight incubation. Pictures were taken at 10X magnification. Invaded cells
were counted in at least three different fields.

Immunofluorescent staining
The paraffin-embedded (FFPE) blocks of fully de-identified ovarian serous
carcinoma were obtained from the Tissue Services Core of the University of Tennessee
Health Science Center (UTHSC). Hematoxylin and eosin (H&E) staining was performed
by Histology Core of UTHSC. To detect DHS, hypusine and EMT genes expression,
ovarian serous carcinoma sections were antigen-retrieved and incubated with blocking
buffer (5% normal goat serum, 3% bovine serum albumin, and 0.1% Triton-X100 in
PBS) for 1 h. The slides were incubated overnight with primary antibodies to DHS,
Cytokeratin-7 (1:200 dilution, Abcam, Cambridge, UK), hypusine (1:200 dilution,
Millipore Sigma, US), and Vimentin (1:200 dilution, Cell Signaling, Danvers, MA).
After rinsing three times for 5 mins with PBST, Alexa 488- or 594- conjugated goat antirabbit or –anti-mouse (Invitrogen, Carlsbad, CA) antibodies were added and incubated
for 1 h at room temperature. Cell nuclei were counterstained with DAPI (Vector
Laboratories, Inc.; Burlingame, CA). Images were captured on a Zeiss LSM700 laser
scanning confocal microscope.

Western blot
Ovarian cancer cells were collected in RIPA buffer (Thermo Scientific; Rockford,
IL) containing 1% Halt Proteinase Inhibitor Cocktail (Thermo Scientific; Rockford, IL).
An equal amount of protein (100 g/lane) was loaded onto 10% SDS-PAGE gels and
transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat
milk for 1 h and incubated with primary antibodies against DHS, hypusine, EIF5A2,
Cytokeratin-7(Abcam), GAPDH (Santa Cruz; St. Louis, MO), Vimentin, Ecadherin, catenin, snail2, Smad2 or p-Smad2 (Cell Signaling).

Orthotopic ovarian cancer mouse model
To test the effect of DHS KO in ovarian cancer cells on ovarian tumor metastasis,
DHS KO and control OVCAR8 cells were labeled with luciferase. 5×105 DHS KO and
control OVCAR8 cells were intrabursally injected into 10 two-months-old
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immunocompromised NOD.Cg Prkdcscid Il2rgtm1Wjl/SzJ (NSG) female mice
(#005557, Jackson Laboratory), (n=5/group). To test the efficacy of GC7, 10 NSG female
mice were intrabursally injected with 5×105 wildtype OVCAR8 cells and randomly
divided into two groups after one-week post-injection. One group of mice were treated
with GC7 (16 mg/kg) and another group of mice were treated with vehicle for 5 days a
week through intraperitoneal injection for 4 weeks. Tumor growth and metastasis were
monitored using the Xenogen bio-imaging system once a week. Mice were sacrificed at 5
weeks after cell injection and primary tumor from ovaries and metastatic tumors from
other peritoneal organs were collected. Xenograft tumors and the peritoneal organs of
each mice were subjected to double-blind histopathologic analysis by a pathologist.

Quantification and statistical analysis
All the statistical analysis of experimental data was carried out in Excel unless
otherwise indicated.
Western blot experiments were repeated independently for three times. SKOV3
and OVCAR8 cells treated with different doses of GC7 (10 M, 50 M and 100 M)
were all compared to vehicle. The protein bands from Western blot were quantified using
ImageJ software and GAPDH was used as a loading control. The statistical significance
of comparisons between two groups was determined by Student’s t-test. ∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001.
The cell survival assay and MTT were performed using three biological
replicates. GC7 treatment with doses of 10 M and 50 M were all compared to vehicle.
The comparisons between two groups were performed using Student’s t-test.
For the migration and invasion assays, cells were counted from three different
fields using ImageJ software. The comparisons between two groups were performed
using Student’s t-test.
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CHAPTER 3. EIF5A2 ENHANCES OVARIAN TUMOR GROWTH AND
METASTASIS BY PROMOTING EPITHELIAL TO MESENCHYMAL
TRANSITION VIA ACTIVATING THE TGF PATHWAY

Introduction
Ovarian cancer has the highest mortality rate among gynecological malignancies
(Siegel et al., 2019). Ovarian cancer patients have few obvious symptoms at early stages
and are often diagnosed at later stage III and IV when tumors have already metastasized
to the peritoneal cavity or other distant abdominal organs such as the omentum, intestine,
liver, spleen and kidney. Early stage ovarian cancer patients respond to chemotherapy,
but eventually become chemotherapy resistant at late stages. Although combinational
approaches are applied for ovarian cancer therapy including debulking surgery,
chemotherapy, targeted therapy and immunotherapy, the five-year survival rate of 35 to
40% is poor (Scalici et al., 2017; Terraneo et al., 2020; Ahmed and Stenvers, 2013;
Lengyel, 2010). The molecular mechanisms underlying ovarian cancer metastasis and
chemoresistance remain unclear. Thus, it is essential to identify new biomarkers for early
diagnosis for ovarian cancer and develop new drugs to improve therapy.
EIF5A is a eukaryotic translation initiation factor that participates in the initiation
and elongation process of protein synthesis. EIF5A is the only protein that undergoes
hypusination through posttranslational modification. The two isoforms of EIF5A,
EIF5A1 and EIF5A2, share sequence similarity of 84% mRNA and 94% protein
(Clement et al., 2003). EIF5A1 is expressed in majority of cell types and is required for
embryonic development, while EIF5A2 is expressed in specific cell types and is not
required for embryonic development (Pällmann et al., 2015). Interestingly, EIF5A2 is
aberrantly amplified or upregulated in many cancers including ovarian cancer, lung,
pancreatic cancer and hepatocellular carcinoma, and contributes to tumor growth and
metastasis (Fujimura et al., 2015; He et al., 2011; Shek et al., 2012; Clement et al., 2003).
Therefore, EIF5A2 is an attractive drug target for cancer therapy based on its aberrant
expression in various cancer types. Although EIF5A2 is upregulated in ovarian cancer, its
functional role has not been well characterized. Previous studies demonstrated that
EIF5A2 contributes to EMT in colorectal, gastric and breast cancer (Zhu et al., 2012; Sun
et al., 2018; Liu et al., 2015b). EMT contributes to tumor initiation, progression, invasion
and metastasis, and EMT is regulated by multiple signaling pathways including ERK1/2,
AKT, WNT in different cancer types (Micalizzi et al., 2010; Drasin et al., 2011; DiMeo
et al., 2009). Although EMT contributes to tumor metastasis, the role of EMT in ovarian
cancer is somewhat controversial due to the similar expression levels of Ecadherin in
ovaries and other distant organs (Ahmed et al., 2007). However, accruing evidence
indicates that EMT plays a key role in ovarian tumor metastasis (Bozhkova and
Poryazova-Markova, 2019; Bhuyan et al., 2019; Antony et al., 2019; Solheim et al.,
2017; Rafehi et al., 2016), our previous studies showed that TGFβ promoted EMT in
ovarian cancer cells (Chen et al., 2014), and activation of the TGFβ pathway contributes
to ovarian tumor metastasis in orthotopic ovarian cancer mouse models (Zhao et al.,
2019).
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Our results identified that EIF5A2 contributes to ovarian tumor growth and
metastasis by promoting EMT. We further uncovered the molecular mechanisms
underlying EIF5A2 mediated EMT in ovarian tumor metastasis.

Results

EIF5A2 expression is amplified or upregulated in ovarian cancer and associated
with poor patient survival
To assess the expression of EIF5A2 in ovarian cancer, we analyzed 607 serous
ovarian carcinomas and 561 normal tissues including 130 ovaries and 431 blood samples
in the Oncomine database (Kandoth et al., 2013). EIF5A2 copy numbers were
significantly amplified in ovarian tumors as compared to normal tissues (p<0.001)
(Figure 3-1A). We also analyzed EIF5A2 expression in multiple cancer types from
TCGA database, and EIF5A2 was amplified across multiple cancer types with the highest
percentage found in lung and ovarian cancer patients (Figure 3-1B). We further
examined the correlation of EIF5A2 copy number and mRNA expression in two different
datasets of TCGA database including 629 serous carcinomas from Firehose Legacy and
608 from PanCancer Atlas. The copy number alteration of EIF5A2 was well-correlated
with mRNA expression based on RNA-seq data (Figure 3-1C). We also examined
EIF5A2 expression from CPTAC (Clinical Proteomic Tumor Analysis Consortium)
database including 100 specimens from ovarian cancer patients and 25 normal ovaries,
which was also found significantly higher in ovarian cancer tissue than that in normal
ovaries at the protein level (Figure 3-1D). We then examined the expression of EIF5A2
in highly invasive SKOV3 and OVCAR8 ovarian cancer cells, and low invasive
OVCAR3 cells using Western blot, and EIF5A2 expression was significantly higher in
both SKOV3 and OVCAR8 cells than that in OVCAR3 cells (Figure 3-2A). To verify
the expression of EIF5A2 in ovarian cancer tissues, we performed immunofluorescent
staining on sections from three ovarian serous carcinoma patients that were verified by
H&E staining. EIF5A2 was strongly stained in the cytoplasm of tumor cells but weakly
stained in the adjacent normal tissues (Figure 3-2B). To determine whether EIF5A2
expression is associated with patient overall survival (OS), we examined the correlation
of EIF5A2 expression with ovarian cancer patient survival based on Kaplan Meier Plotter
of 655 ovarian cancer samples including 383 with high EIF5A2 expression and 272 with
low expression (Győrffy et al., 2012). The OS was significantly reduced in patients with
EIF5A2 high expression as compared to low expression patients (Figure 3-1E). We also
examined additional 415 ovarian carcinoma including 207 EIF5A2 high and 208 low in
the SurvExpress database (Aguirre-Gamboa et al., 2013) and EIF5A2 expression was
analyzed based on risk groups. EIF5A2 expression was significantly higher in the highrisk group than that in low-risk group (Figure 3-2C), and the OS was significantly
reduced in high-risk compared to low-risk group (Figure 3-1F). EIF5A2 expression was
well-correlated with poor ovarian patient survival.
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Figure 3-1. EIF5A2 expression is amplified or upregulated in ovarian cancer and
associated with poor patient survival.
(A) EIF5A2 copy numbers in normal and cancer tissues. 1: normal ovaries (n=130); 2:
normal blood (n=431); 3: ovarian cancer (n = 607), p<0.001. (B) EIF5A2 is amplified in
majority of cancer types from in TCGA database. (C) EIF5A2 copy number is correlated
with EIF5A2 mRNA expression from RNA-seq in two different datasets including
TCGA PanCancer and firehose legacy. (D) Protein expression of EIF5A2 in normal and
ovarian cancer tissues. Normal ovaries (n=25), Ovarian cancer (n=100), p<0.001. (E)
EIF5A2 expression is associated with overall survival of ovarian cancer patients in
Kaplan Meier Plotter database, p<0.001. (F) Ovarian cancer patients displayed
significantly reduced patient survival in the high-risk compared to the low-risk group,
p<0.01.
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Figure 3-2. EIF5A2 expression in ovarian cancer cell line and tissues.
(A) Endogenous EIF5A2 expression in OVCAR3, SKOV3 and OVCAR8 cells. One
representative Western blot was presented from three similar independent experiments.
Band intensity was measured using ImageJ and the significance was determined by
student’s T-test. (***p<0.001). (B) Ovarian cancer sections immunofluorescent stained
with EIF5A2 (green) and PCNA (red) antibodies and cell nuclei were counterstained with
DAPI (blue) (n=3). (C) EIF5A2 expression is significantly higher in the high-risk group
than that in the low risk group in 415 ovarian carcinoma samples in the SurvExpress
database, p<0.001.
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EIF5A2 promotes EMT in ovarian cancer cells
Based on their expression level of EIF5A2, to determine whether EIF5A2
contributes to EMT phenotypic switch, we knocked out EIF5A2 in highly invasive
SKOV3 and OVCAR8 cells using lentiviral CRISPR/Cas9 nickase vector, and
overexpressed EIF5A2 in low invasive OVCAR3 cells using lentiviral vector under the
control of EF1α promoter. EIF5A2 was undetectable in both SKOV3 and OVCAR8 KO
cells, while EIF5A2 expression was remarkably increased in EIF5A2 overexpression
OVCAR3 cells compared to control cells. The EMT markers including the epithelial cell
marker Cytokeratin-7 and Ecadherin were upregulated while mesenchymal markers
including β-catenin, Vimentin and snail2 were downregulated in both SKOV3 and
OVCAR8 KO compared to control cells (Figure 3-3A). In contrast, overexpression of
EIF5A2 in OVCAR3 cells resulted in the downregulation of epithelial cell markers
Cytokeratin-7 and Ecadherin, while mesenchymal markers including β-catenin, Vimentin
and snail2 were upregulation compared to control cells (Figure 3-3B).

Loss of EIF5A2 expression inhibits ovarian cancer cell proliferation and survival
To determine the functional outcome of loss of EIF5A2 expression in ovarian
cancer cells, we examined cell survival in EIF5A2 knockout and control SKOV3 and
OVCAR8 cells by cell colony formation assays. Results show that loss of EIF5A2
expression led to significant inhibition in both SKOV3 (Figure 3-4A) and OVCAR8
(Figure 3-4B). Gain function of EIF5A2 enhanced cell survival in OVCAR3 cells
(Figure 3-4C). In addition, we examined cell proliferation in EIF5A2 KO and control
SKOV3 and OVCAR8 cells by performing MTT assays. Disruption of EIF5A2 by
CRISPR/Cas9 nickase significantly reduced cell proliferation compared to controls at all
three time points (24, 48, and 72 h) in both SKOV3 and OVCAR8 cells (Figure 3-4D,
E). EIF5A2-expressing OVCAR3 cells promoted cell proliferation at a time-dependent
manner (Figure 3-4F).

Loss of EIF5A2 expression inhibits ovarian cancer cell migration and invasion
EMT contributes to tumor cell migration and invasion. Since we found that
EIF5A2 promoted EMT in ovarian cancer cells (Figure 3-3), we determine the role of
EIF5A2 in migration and invasion of ovarian cancer cells using transwell plates. KO of
EIF5A2 significantly inhibited migration (Figure 3-5A) and invasion (Figure 3-5B) in
SKOV3 and OVCAR8 cells, while overexpression of EIF5A2 significantly enhanced
migration (Figure 3-5C) and invasion in OVCAR3 (Figure 3-5D).
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Figure 3-3. Disruption of EIF5A2 expression using lentiviral CRISPR/Cas9
nickase-mediated editing resulted in the inhibition of EMT in ovarian cancer cells.
(A) Western blot analysis of EIF5A2 and EMT markers in EIF5A2 KO and control (Con)
SKOV3 and OVCAR8 cells (n=3). (B) Western blot analysis of EIF5A2 and EMT
markers in EIF5A2 expression and control OVCAR3 cells (n=3). Band intensity was
measured using ImageJ and the significance was determined by student’s T-test. One
representative Western blot was presented from three similar independent experiments.
(*p<0.05, **p<0.01, *** p<0.001).
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Figure 3-4. Disruption of EIF5A2 expression led to the inhibition of cell
proliferation and survival in ovarian cancer cells.
(A, B) Cell survival in EIF5A2 knockout and control SKOV3 and OVCAR8 cells was
determined by colony formation assay (n=3, **p<0.01; ***p<0.001). (C) Cell survival in
EIF5A2-expressing and control OVCAR3 cells was determined by colony formation
assay (n=3, *p <0.05). (D, E) Cell proliferation in EIF5A2 knockout and control SKOV3
and OVCAR8 cells was determined by MTT assay (n=3, *p <0.05; **p <0.01). (F) Cell
proliferation in EIF5A2-expressing and control OVCAR3 cells was determined by MTT
assay (n=3, **p<0.01).
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Figure 3-5. Disruption of EIF5A2 expression led to the inhibition of cell migration
and invasion in ovarian cancer cells.
(A) Cell migration in EIF5A2 knockout and control SKOV3 or OVCAR8 cells was
examined using transwell plates, and migrated cells were stained with crystal blue and
counted (n=3, **p<0.01). (B) Cell invasion in both EIF5A2 knockout and control
SKOV3 or OVCAR8 cells was examined using Matrigel-coated plates, and invaded cells
were stained with H&E and counted (n=3, **p<0.01; ***p <0.001). (C) Cell migration in
EIF5A2-expressing and control OVCAR3 cells was examined using transwell plates, and
migrated cells were stained with crystal blue and counted (n=3, **p<0.01). (D) Cell
invasion in EIF5A2-expressing OVCAR3 cells was examined using Matrigel-coated
plates, and invaded cells were stained with H&E and counted (n=3, **p<0.01).
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EIF5A2/TGFβ forms a positive feedback loop in promoting EMT in ovarian cancer
cells
Previously, we reported that TGFβ promoted EMT in ovarian cancer cells (Chen
et al., 2014). To understand how EIF5A2 contributed to EMT in ovarian cancer cells, we
examined the correlation between EIF5A2 and TGFβ pathway in ovarian cancer cells by
treating both SKOV3 and OVCAR8 cells with 6 ng/ml TGFβ. As shown in Figure 3-6A,
TGFβ induced EIF5A2 expression in a time-dependent manner in both cell lines. We also
treated both SKOV3 and OVCAR8 cells for 24 h with different doses of TGFβR1/2
inhibitor SB431542 and EIF5A2 expression was inhibited in a dose-dependent manner in
both cell lines (Figure 3-6B). In addition to pharmacological approach, we used genetic
approach by knocking down (KD) TGFβ receptor 2 (TGFβR2) using a lentiviral
CRISPR/Cas9 nickase vector and then treated both TGFβR2 KD and control cells with 6
ng/ml TGFβ for 24 h and examined EIF5A2 expression. KD of TGFβR2 significantly
reduced EIF5A2 protein levels in both SKOV3 and OVCAR8 cells, while TGFβ induced
EIF5A2 expression in control but not in the KD cells (Figure 3-6C), indicating that
TGFβ promoted EIF5A2 expression.
To examine how EIF5A2 regulates the TGFβ pathway, EIF5A2 KO SKOV3 and
OVCAR8 cells and control cells were treated with 6 ng/ml TGFβ. Phospho- and total
Smad2 in EIF5A2 KO and control ovarian cancer cells were examined by Western blot.
Loss of EIF5A2 attenuated the TGFβ pathway as shown by the reduced phospho-Smad2
in both SKOV3 and OVCAR8 compared to control cells (Figure 3-6D). We further
examined the TGFβ signaling by treating both EIF5A2 overexpression and control
OVCAR3 cells with 6 ng/ml TGFβ. As we expected, overexpression of EIF5A2 activated
the TGFβ pathway as shown by increased phospho-Smad2 in EIF5A2 overexpression
OVCAR3 cells compared to control cells (Figure 3-6E).
To further examine the interaction of EIF5A2 and TGFβ signaling pathway, we
transduced EIF5A2 KO, overexpression and control cells with a lentiviral luciferase
reporter construct containing six Smad2/3/4 response elements upstream of CMV minipromoter and then treated transduced cells with 6 ng/ml TGFβ for 12 h. Loss of EIF5A2
significantly inhibited the luciferase activity in both SKOV3 and OVCAR8 cells while
overexpression of EIF5A2 enhanced luciferase activity in OVCAR3 cells (Figure 3-7).
Our data indicated that EIF5A2 forms a positive feedback loop with TGFβ pathway in
ovarian cancer cells.

Loss of EIF5A2 suppresses primary ovarian tumor growth and metastasis by
inhibiting EMT and attenuating TGFβ pathway in an orthotopic ovarian cancer
mouse model
To determine whether EIF5A2 contributes to primary ovarian tumor growth and
metastasis, we intrabursally injected 5×105 ovarian cancer SKOV3 EIF5A2-KO and
control cells into two-month-old immunocompromised NSG female mice. The primary
ovarian tumors were significantly reduced in mice injected with EIF5A2 KO cells than
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Figure 3-6. The association of EIF5A2 with the TGFβ pathway and inhibition of
EIF5A2-attenuated TGFβ signaling pathway in ovarian cancer cells.
(A) TGFβ induced EIF5A2 in SKOV3 and OVCA8 cells at the indicated time points as
detected by Western blot (n=3, **p<0.01). (B) TGFβR1/2 inhibitor SB431542 reduced
EIF5A2 expression in SKOV3 and OVCAR8 cells at the indicated dose points for 24 has
detected by Western blot (n=3, *p<0.05, **p <0.01). (C) Western blot analysis and
comparison of EIF5A2 in TGFβR2 KD and control SKOV3 and OVCAR8 cells
following 6 ng/ml TGFβ treatment for 24 h, respectively (n=3, **p<0.01, ***p<0.001).
(D) The expression of phospho- and total Smad2 in EIF5A2 knockout and control
SKOV3 and OVCAR8 cells was detected by Western blot following 6 ng/ml TGFβ
treatment at the indicated time points (n=3, *p<0.05; **p <0.01; *** p<0.001). (E) The
expression of phosphor- and total Smad2 in EIF5A2 overexpression and control
OVCAR3 cells was detected by Western blot following 6 ng/ml TGFβ treatment at the
indicated time points (n=3, **p<0.01). One representative Western blot was presented
from three similar independent experiments. Band intensity was measured using ImageJ
and the significance was determined by student’s T-test.
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Figure 3-7. Smad-dependent reporter gene luciferase activity.
Luciferase activity in EIF5A2 KO and control SKOV3 and OVCAR8 cells (A, B) or
EIF5A2 expressing and control OVCAR3 cells (C) transduced with pGreenFire1Smad2/3/4-GF-EF1-puro lentiviral vector following 6 ng/ml TGFβ treatment for 12 h
(n=3, *p<0.05, *** p<0.001).
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control mice as shown by tumor weight (Figure 3-8A). We then examined EIF5A2, EMT
markers and p-Smad2 expression in primary ovarian tumors by Western blot. EIF5A2
and mesenchymal markers including β-catenin, snail2, and Vimentin and p-Smad2 were
downregulated, while the epithelial markers Cytokeratin-7 and Ecadherin were
upregulated in tumors of mice implanted with EIF5A2 KO SKOV3 compared to control
cells (Figure 3-8B). Ovarian tumors were also characterized by H&E staining (Figure 38C). Ovarian tumor sections were immunostained with EIF5A2, Vimentin and
Cytokeratin-7 antibodies. EIF5A2 and Vimentin were weakly stained, while Cytokerain7 was strongly stained in tumors from mice xenografted with KO cells than control cells
(Figure 3-9). We further found metastatic tumors in multiple peritoneal organs including
the liver and spleen of mice injected with control cells, but less metastasis in mice
implanted with EIF5A2 KO cells as shown by bioluminescence and H&E staining
(Figure 3-10). Our results indicated that loss of EIF5A2 suppressed primary ovarian
tumor growth and tumor metastasis by inhibiting EMT and attenuating TGFβ pathway in
orthotopic ovarian cancer mouse models.

Discussion
Lacking an effective biomarker is a major issue for early diagnosis of ovarian
cancer patients. We report that EIF5A2 is a potential biomarker for early diagnosis of
ovarian cancer and prognosis following chemotherapy. In particular, EIF5A2 is
correlated with poor ovarian cancer patient survival. For the first time we demonstrated
that EIF5A2 contributes to ovarian tumor metastasis by promoting EMT and activating
the TGFβ pathway. EIF5A2 was shown to associate with metastasis, developmental
stages, histological types and poor patient survival in gallbladder cancer, oral squamous
cell carcinoma (Lin et al., 2020), prostate cancer (Lu et al., 2019), cervical cancer (Yang
et al., 2016b), and hepatocellular carcinoma (Lee et al., 2010). In the present study, we
analyzed the expression of EIF5A2 in high grade serous ovarian carcinoma in TCGA and
other databases and found that EIF5A2 was associated with tumor metastasis and poor
patient survival. It remains to be addressed on the correlation between EIF5A2
expression level and different stages or grades in other types of ovarian cancer including
clear cell, endometrioid and mucinous carcinomas. Our studies indicate that EIF5A2 is a
potential biomarker for diagnosis and prognosis as well as an attractive drug target due to
its low expression in normal tissues and high expression in ovarian tumors.
Using gain and loss of functional approaches through lentiviral vector-based gene
editing and overexpression, we showed for the first time that EIF5A2 promoted EMT in
ovarian cancer cells, suggesting that EIF5A2 may contribute to ovarian cell invasion and
metastasis. KO of EIF5A2 not only inhibited primary ovarian tumor growth and
clonogenicity but also inhibited ovarian tumor metastasis in orthotopic ovarian cancer
mouse models (Figure 3-8 through 3-10). Our finding is consistent with previous studies
that EIF5A2 was also shown to promote EMT and contribute to cell invasion,
chemoresistance and metastasis in several caner types including HCC (Tang et al., 2010),
colorectal cancer (Zhu et al., 2012), bladder cancer (Wei et al., 2014) and OSCC (Lin et
al., 2020). Therefore, targeting EIF5A2 may inhibit tumor metastasis and overcome
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Figure 3-8. Knockout of EIF5A2 using lentiviral CRISPR/Cas9 nickase vector
suppressed primary ovarian tumor growth in an orthotopic ovarian cancer mouse
model.
(A) Primary ovarian tumors dissected at one month following intrabursally injection of
EIF5A2 KO and control SKOV3 cells. Tumor weight in EIF5A2-KO is significantly less
than in control (n=5, ***p<0.001). (B) Western blot and densitometry analysis of
EIF5A2, p-Smad2 and EMT markers from primary tumor of mice xenografted with
EIF5A2 KO and control cells (n=3, *p<0.05, **p<0.01). Band intensity was measured
using ImageJ and the significance was determined by student’s T-test. (C) Sections of
primary ovarian tumors were stained with H&E.
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Figure 3-9. EIF5A2 and EMT markers were stained in sections of ovarian tumor
of EIF5A2 KO and control mice.
(A, B, C) Ovarian cancer sections were stained by EIF5A2, Vimentin and Cytokeratin-7
antibodies (green) and for cell proliferation was stained with PCNA antibody (red). Cell
nuclei were counterstained with DAPI. Sections were also stained with H&E.
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Figure 3-10. Knockout of EIF5A2 using lentiviral CRISPR/Cas9 nickase vector
suppressed ovarian tumor metastasis in an orthotopic ovarian cancer mouse model.
(A) Metastatic tumors in liver and spleen of mice xenografted with EIF5A2 KO and
control (Con) cells (n=5, **p<0.01; ***p<0.001). (B) Sections of metastatic tumors in
liver and spleen were stained with H&E.
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chemoresistance by reversing EMT in cancer cells. EIF5A2 is the only hypusinated
protein and matured through hypusination pathway and DHS is the first enzyme in the
pathway leading to EIF5A2 maturation. A DHS small molecular inhibitor GC7 has been
used to disrupt the hypusination pathway. GC7 has been shown to inhibit EMT in
hepatocellular carcinoma (Lou et al., 2013), bladder cancer (Wei et al., 2014) and breast
cancer (Liu et al., 2015b). Inhibition of EIF5A2 maturation may suppress tumor
metastasis by reversing EMT using GC7 (Liu et al., 2015b; Zhou et al., 2017). Therefore,
targeting EIF5A2 hypusination using DHS inhibitor may be a new approach for cancer
therapy including ovarian cancer.
Although we showed that EIF5A2 promoted EMT in ovarian cancer cells, the
molecular mechanisms by which EIF5A2 regulates EMT remains unclear. We previously
showed that TGFβ promotes EMT in ovarian cancer (Chen et al., 2014). Interestingly, we
found that TGFβ induced EIF5A2 expression, while inhibition of TGFβR1/2 using
SB431542 or knockdown of TGFβR2 suppressed EIF5A2 expression. KO of EIF5A2
attenuated TGFβ pathway, while overexpressing EIF5A2 activated TGFβ pathways. Our
studies indicated a positive feedback loop between EIF5A2 and the TGFβ pathway in
ovarian cancer cells. Previous studies also showed that EIF5A2 is involved in TGFβ
pathway (Hao et al., 2020; Wei et al., 2014). TGF increases and sustains the
hypusination of EIF5A1 and EIF5A2 in high-grade metastatic breast cancer (Güth et al.,
2019). However, EIF5A2 is negatively correlated with TGFβ signaling in the anaplastic
thyroid carcinoma (Hao et al., 2020) whereas EIF5A2 was positively correlated with
TGFβ signaling in bladder cancer by stabilizing STAT3 binding the TGFβR1 promoter
(Wei et al., 2014). EIF5A2 was also post-transcriptionally upregulated by hnRNPE1
through binding 3’ untranslated region in a TGFβ-dependent manner in NMuMG cells
(Hussey et al., 2012). Our studies indicated a positive feed-back loop between EIF5A2
and TGFβ signaling pathway, which may contribute to ovarian cancer cell invasion and
metastasis by promoting EMT. However, it is still not clear how EIF5A2 interacts with
TGFβ pathway. Based on luciferase reporter gene assay, it is possible that Smad2/3/4
may bind the promoter of EIF5A2 and activate EIF5A2 expression as we showed that
TGFβ induced luciferase reporter expression in EIF5A2 expressing cells, but not the
EIF5A2 KO cells (Figure 3-7).
Collectively, our study demonstrated that EIF5A2 is highly expressed in ovarian
HGSC and associated with poor patient survival. EIF5A2 promotes primary ovary tumor
growth and metastasis by promoting EMT and activating the TGFβ pathway.
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CHAPTER 4. DISRUPTION OF HYPUSINATION PATHWAY INHIBITS
PRIMARY OVARIAN TUMOR GROWTH AND METASTASIS

Introduction
Ovarian cancer accounts for more deaths than any other types of gynecologic
cancer and is therapeutically challenging. The majority of ovarian cancer patients die
from advanced, high-grade serous carcinoma with widespread metastasis in the peritoneal
cavity (Chandra et al., 2019). One of the reasons why ovarian cancer is rarely detected at
early stages is because it metastasizes early and mostly through intraperitoneal
dissemination to directly invade either neighboring or distant organs (Eisenkop and
Spirtos, 2001; Lengyel, 2010). Therefore, understanding the regulatory mechanisms
underlying ovarian cancer metastasis is crucial for ovarian cancer treatment.
EMT has recently received great attention in ovarian research and many studies
support the role of EMT in ovarian cancer metastasis (Lili et al., 2013; Ahmed et al.,
2010; Yan and Sun, 2014). In Chapter 3, our results found that EIF5A2 is highly
expressed in ovarian cancer patients and correlated with poor patient survival. We also
demonstrated that EIF5A2 contributes to EMT via activating the TGF pathway and KO
of EIF5A2 suppresses ovarian primary tumor growth and metastasis.
The posttranslational hypusine modification is required for EIF5A to be maturated
and functional (Caraglia et al., 2013). Hypusine was firstly isolated from bovine brain
extracts by Shiba and coworkers in 1971 (Shiba et al., 1971). The EIF5A hypusination of
was first discovered in Park’s laboratory from human lymphocytes cultured in a medium
containing radioactive spermidine and analyzed the radiolabeled proteins using twodimensional gel electrophoresis in 1981 (Park et al., 1981). Later studies found that
hypusine formation occurs at the Lys50 of N-terminal of precursor-EIF5A (Park et al.,
1993).
DHS and DOHH are enzymes involved in the posttranslational modification of
hypusine in EIF5A (Mathews and Hershey, 2015; Wang et al., 2013). DHS and DOHH
apparently only function in the hypusination of EIF5A (Park and Wolff, 2018). This
unique feature makes the polyamine-hypusine pathway an attractive target for cancer
prognosis, prevention, and therapeutic treatment.
The hypusination pathway can be blocked by inhibiting the association of
spermidine with DHS to specifically control EIF5A maturation and suppress tumor
progression in several human cancers (Jakus et al., 1993). GC7 is one of the most
competitive DHS inhibitors (Jakus et al., 1993). Multiple studies show that GC7 can
reduce the metastatic dissemination of tumor cells through the inhibition of EIF5A
hypusination in different human cancers, including breast cancer (Güth et al., 2019), oral
squamous cell carcinoma (Fang et al., 2018b), and neuroblastoma (Bandino et al., 2014).
Also blocking EMT by GC7 reverses hypoxia-induced chemotherapy resistance in
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hepatocellular carcinoma cells (Zhou et al., 2017). However, it is not known whether
GC7 inhibits EIF5A2 expression in ovarian cancer cells.
Our results identified that disruption of hypusination pathway by inhibition of
DHS suppresses primary ovarian tumor growth and metastasis. We also demonstrated
that KO of DHS or using GC7 can inhibit hypusination of EIF5A2 and reduce ovarian
tumor growth and metastasis in an orthotopic ovarian cancer mouse model.

Results

Disruption of DHS expression using lentiviral CRISPR/Cas9 nickase-mediated
editing inhibits hypusinated EIF5A, EIF5A2, and EMT in ovarian cancer cells
As discussed in Chapter 3, SKOV3 and OVCAR8 cell lines have high
endogenous EIF5A2 expression. To determine whether blocking the hypusination
modification of EIF5A2 inhibits EMT in ovarian cancer cells, we constructed lentiviral
CRISPR/Cas9 nickase by using two gRNAs targeting the region of exon 1 of DHS. The
lentiviral CRISPR/Cas9 nickase vector was then transduced into both SKOV3 and
OVCAR8 cells and selected with 2 μg/ml puromycin following 10 g/ml blasticidin
selection. Using Western blot, we examined the alteration of DHS, hypusinated EIF5A,
and EIF5A2, and EMT-associated markers in SKOV3 and OVCAR8 cells. DHS was
remarkably depleted in both SKOV3 and OVCAR8 cells transduced with lentiviral DHS
gRNA vector compared to control cells. Accordingly, hypusinated EIF5A was reduced in
both DHS KO SKOV3 and OVCAR8 cells. EIF5A2 expression and EMT markers were
also altered by upregulation of epithelial cell markers Cytokeratin-7 and Ecadherin and
downregulation of mesenchymal cell marker β-catenin, Vimentin, and Snail2 compared
to control cells (Figure 4-1A, B). We further examined hypusinated EIF5A, EIF5A2, and
EMT marker gene expressions by treating both SKOV3 and OVCAR8 cells with
different doses of GC7. Hypusinated EIF5A, EIF5A2, and the mesenchymal markers catenin, Vimentin, and Snail2 were downregulated while the epithelial markers
Cytokeratin-7 and Ecadherin were upregulated following dose-dependent inhibition of
DHS (Figure 4-2A, B).

Disruption of DHS expression inhibits cell proliferation and survival in ovarian
cancer cells
To determine the functional role of the loss of DHS expression in ovarian cancer
cells, we examined cell survival in DHS KO and control SKOV3 and OVCAR8 cells by
using cell colony formation assay. Results showed that loss of DHS expression led to
significant inhibition of cell survival in both SKOV3and OVCAR8 cells (Figure 4-3A,
B). We examined cell proliferation in DHS KO and control SKOV3 and OVCAR8 cells
by performing the MTT assays. KO of DHS significantly reduced proliferation compared
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Figure 4-1. Disruption of DHS expression using lentiviral CRISPR/Cas9 nickasemediated editing resulted in the inhibition of hypusinated EIF5A, EIF5A2 and EMT
in ovarian cancer cells.
(A, B) Hypusinated EIF5A, EIF5A2, and EMT marker gene expression was examined in
DHS knockout and control SKOV3 and OVCAR8 cells by using Western blot (n=3,
**p<0.01, ***p<0.001). One representative Western blot was presented from three
similar independent experiments. Band intensity was measured using ImageJ and the
significance was determined by student’s T-test.
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Figure 4-2. GC7 inhibited hypusinated EIF5A, EIF5A2 and EMT in ovarian
cancer cells.
(A, B) Hypusinated EIF5A, EIF5A2 and EMT marker gene expression was examined in
(0, 10, 50, 100 M) GC7- and vehicle- treated SKOV3 and OVCAR8 cells by using
Western blot (n=3, **p<0.01, ***p <0.001). One representative Western blot was
presented from three independent experiments. Band intensity was measured using
ImageJ and the significance was determined by student’s T-test.
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Figure 4-3. Disruption of DHS expression led to the inhibition of cell survival and
proliferation in ovarian cancer cells.
(A, B) Cell survival in DHS KO and control SKOV3 and OVCAR8 cells was determined
by colony formation assay (n=3, *p<0.05; **p <0.01). (C, D) Cell proliferation in DHS
KO and control SKOV3 and OVCAR8 cells was determined by MTT assay (n=3, *p
<0.05; **p <0.01).
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to control cells at all three different time points (24, 48, and 72 h) in both SKOV3 and
OVCAR8 cells (Figure 4-3 C, D). In addition, we tested the effect of GC7 on cell
survival by treating SKOV3 and OVCAR8 cells with 20 M of GC7 and found that GC7
significantly inhibited cell survival based on the colony formation assay (Figure 4-4A,
B). To examine how GC7 affects cell proliferation, we treated both SKOV3 and
OVCAR8 cells with three different doses of GC7 (0, 10, 20 M) at four different time
points (24, 48, 72 and 96 h). Results showed that cell proliferation was significantly
inhibited in both SKOV3 and OVCAR8 cells at those time points (Figure 4-4C, D).

Disruption of DHS expression inhibits cell migration and invasion in ovarian cancer
cells
Loss of DHS inhibits EMT in ovarian cancer cells, suggesting that blocking of
hypusination of EIF5A2 affects cell motility and invasion. Using transwell plates, we
examined cell migration in DHS KO and control cells and found that cell migration was
significantly reduced in both DHS KO and control SKOV3 and OVCAR8 cells (Figure
4-5A). Using Matrigel-coated transwells, we assessed cell invasion, which was also
significantly reduced in both DHS KO SKOV3 and OVCAR8 compared to control cells
(Figure 4-5B). To test whether GC7 has a similar effect on cell migration and invasion,
wild type SKOV3 and OVCAR8 cells were treated with 20 M GC7 for 4 h following
pre-treatment of 20 M Z-VAD for 2 h by inhibiting cell proliferation, and cell migration
and invasion were determined with the same methods. Our results showed that inhibition
of DHS with GC7 significantly reduced cell migration and invasion in both cell lines
(Figure 4-6A, B).
Blocking of hypusination of EIF5A2 attenuates TGFβ signaling pathway in ovarian
cancer cells
To examine whether blocking of hypusination affects the TGFβ pathway in
ovarian cancer cells, we treated DHS KO and control SKOV3 and OVCAR8 cells with 6
ng/ml TGFβ at different time points (0, 10 and 20 mins) and then examined phosphoSmad2 and total Smad2 by using Western blot. Loss of DHS resulted in the attenuation of
TGFβ signaling pathway as showed by reduced phospho-Smad2 (Figure 4-7A, B). We
also determined the TGFβ pathway following 20 M GC7 treatment and found that
inhibition of DHS attenuated phospho-Smad2 in both SKOV3 and OVCAR8 cells
(Figure 4-7C, D). Our data indicated that disruption of hypusination of EIF5A2 inhibited
the TGFβ pathway in ovarian cancer cells.

KO of DHS using lentiviral CRISPR/Cas9 nickase vector suppresses primary
ovarian tumor growth and metastasis in an orthotopic ovarian cancer mouse model
We found that KO of EIF5A2 in SKOV3 cells led to the suppression of primary
ovarian tumor growth and metastasis. To test whether disruption of hypusination inhibits
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Figure 4-4. GC7 inhibited cell survival and proliferation in ovarian cancer cells.
(A, B) Cell survival was determined in 20 M GC7- and vehicle- treated SKOV3 and
OVCAR8 cells by colony formation assay (n=3, **p <0.01; ***p <0.001). (C, D) Cell
proliferation was determined using 10 and 20 M of GC7 treatment at different time
points in SKOV3 and OVCAR8 cells by MTT assay (n=3, *p <0.05; **p <0.01; ***p
<0.001).
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Figure 4-5. Disruption of DHS expression inhibited cell migration and invasion in
ovarian cancer cells.
(A) Cell migration was examined in DHS KO and control SKOV3 or OVCAR8 cells
using transwell plates, and migrated cells were stained with crystal violet and counted
(n=3, **p<0.01; ***p <0.001). (B) Cell invasion in both DHS KO and control SKOV3 or
OVCAR8 cells was examined using Matrigel-coated plates, and invaded cells were
stained with H&E and counted (n=3, *p<0.05; **p <0.01).
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Figure 4-6. GC7 inhibited cell migration and invasion in ovarian cancer cells.
(A) Cell migration was examined in 20 M GC7- and vehicle- treated SKOV3 or
OVCAR8 cells using transwell plates, and migrated cells were stained with crystal violet
and counted (n=3, **p<0.01). (B) Cell invasion was examined in 20 M GC7- and
vehicle- treated SKOV3 or OVCAR8 cells using Matrigel-coated plates, and invaded
cells were stained with H&E and counted (n=3, **p <0.01).

47

Figure 4-7. Inhibition of DHS attenuated the TGFβ signaling pathway in ovarian
cancer cells.
(A, B) The expression of phospho- and total Smad2 in DHS KO and control SKOV3 and
OVCAR8 cells was detected by Western blot following 6 ng/ml TGFβ treatment at the
indicated time points (n=3, **p<0.01; *** p<0.001). (C, D) The expression of phosphoand total Smad2 was detected by Western blot in SKOV3 and OVCAR8 cells following
20 M GC7 for 12 h and then treated with 6 ng/ml TGFβ at the indicated time points
(n=3, *** p<0.001). Band intensity was measured using ImageJ and the significance was
determined by student’s T-test. One representative Western blot was presented from three
similar independent experiments.
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primary ovarian tumor growth and metastasis, we established a stable DHS KO
OVCAR8 cell line with lentiviral CRISPR/Cas9 nickase vector as described in Chapter 2.
We then intrabursally injected 5×105 ovarian cancer DHS KO and control OVCAR8 cells
into two-month-old immunodeficient NSG female mice. Tumor growth and metastasis
were monitored weekly using live animal imaging. After 5 weeks following cell
injection, all mice xenografted with DHS KO OVCAR8 and control cells were sacrificed
and tumors in ovaries were collected. Primary tumors were significantly smaller in mice
injected with DHS KO cells compared to tumors injected with control cells when mice
were either imaged using bioluminescence or sacrificed (Figure 4-8A, B). The primary
tumors were characterized by H&E staining (Figure 4-8C).
We further examined multiple peritoneal organs and found that tumors mainly
metastasized into the liver and spleen of mice injected with control cells (Figure 4-9A).
In contrast, mice injected with DHS KO of OVCAR8 cells showed reduced metastatic
tumors in those organs. The metastasized tumors were characterized by staining with
H&E (Figure 4-9B). We examined hypusinated EIF5A, EIF5A2, EMT markers and pSmad2 expression in primary ovarian tumors using Western blot. KO of DHS inhibited
hypusinated EIF5A and EIF5A2 expression and downregulated the mesenchymal
markers including β-catenin, Snail2, and Vimentin and p-Smad2 expression, and
upregulated the epithelial marker Cytokeratin-7 and Ecadherin (Figure 4-9C). Tumor
sections of mouse ovaries were immunostained with DHS, Vimentin, Cytokeratin-7 and
hypusinated EIF5A antibodies, and the results were consistent with the Western blots
(Figure 4-10). Our results indicated that blocking of hypusination suppressed primary
ovarian tumor growth and metastasis by inhibiting EMT and attenuating the TGFβ
pathway in orthotopic ovarian cancer mouse model.

GC7 suppresses primary ovarian tumor growth and metastasis in an orthotopic
ovarian cancer mouse model
Knockout of DHS inhibited primary tumor growth in ovaries and tumor
metastasis in multiple peritoneal organs (Figure 4-8 through 4-10). To test whether GC7
suppresses ovarian tumor metastasis by inhibiting DHS, we examined the efficacy of
GC7 using an orthotopic ovarian cancer mouse model by intrabursally injecting
OVCAR8- Luc2 cells into two-month-old immunodeficient NSG female mice and then
treated mice with 16 mg/kg of GC7 for 5 days a week through intraperitoneal injection
for 4 weeks. Tumor growth and metastasis were monitored using live animal imaging,
and ovarian tumor metastasis was observed approximately two weeks after cell injection.
At the 5th week following cell injection, tumors were dissected, and primary ovarian
tumors were significantly reduced in GC7 treated mice compared to control mice (Figure
4-11A, B). The primary tumors were characterized by H&E staining (Figure 4-11C). We
further examined multiple peritoneal organs and found that tumors metastasized into the
liver and spleen of mice injected with control cells. In contrast, mice treated with GC7
did not display detectable metastatic tumors in those organs (Figure 4-12A). The
metastasized tumors were characterized by H&E (Figure 4-12B). We examined
hypusinated EIF5A, EIF5A2, EMT markers, and p-Smad2 expression in primary ovarian
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Figure 4-8. Knockout of DHS using lentiviral CRISPR/Cas9 nickase vector
suppressed primary ovarian tumor growth in an orthotopic ovarian cancer mouse
model.
(A) Bioluminescence of primary ovarian tumors dissected at one month following
intrabursally injection of DHS KO and control OVCAR8 cells (n=5, **p <0.01). (B)
Primary ovarian tumors dissected at 5 weeks following intrabursally injection of DHS
KO and control OVCAR8 cells. Tumor weight in DHS KO is significantly less than in
control (n=5, **p <0.01). (C) Primary tumors of mice xenografted with DHS KO and
control cells were stained by H&E.
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Figure 4-9. Knockout of DHS using lentiviral CRISPR/Cas9 nickase vector
suppressed ovarian tumor metastasis in an orthotopic ovarian cancer mouse model.
(A) Metastatic tumors in liver and spleen of mice xenografted with DHS KO and control
cells were shown by bioluminescence images (n=5, **p <0.01). (B) Metastatic tumors in
liver and spleen of mice xenografted with DHS KO and control cells were stained by
H&E. (C) Western blot and densitometry analysis of DHS, hypusinated EIF5A, EIF5A2,
p-Smad2 and EMT markers from primary ovarian tumor in mice xenografted with DHS
KO and control cells (n=3, *p <0.05;**p <0.01;***p <0.001). Band intensity was
measured using ImageJ and the significance was determined by the student’s T-test.
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Figure 4-10. DHS and EMT markers were stained in sections of ovarian tumor of
DHS KO and control mice.
(A, B, C, D) DHS and Hypusinated EIF5A (green) was stained in cell cytoplasm, PCNA
(red) was stained in cell nuclei and Cytokeratin-7 (green) and Vimentin (green) were
stained in cell membranes of tumors from xenografted mice with DHS KO and control
OVCAR8 cells. The sections of ovarian tumors were also stained with H&E.
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Figure 4-11. GC7 suppressed primary ovarian tumor growth in an orthotopic
ovarian cancer mouse model.
(A) Primary ovarian tumor weight in GC7 and vehicle treated mice (n=5, ***p <0.001).
(B) Primary ovarian tumors were shown using bioluminescence images (n=5, ***p
<0.001). (C) Primary ovarian tumors were stained with H&E in GC7 and vehicle treated
mice.
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Figure 4-12. GC7 suppressed ovarian tumor metastasis in an orthotopic ovarian
cancer mouse model.
(A) Metastatic tumors in liver and spleen of mice xenografted treated with GC7 and
vehicle were shown by bioluminescence images (n=5, ***p <0.001). (B) Metastatic
tumors in liver and spleen of mice xenografted treated with GC7 and vehicle were stained
by H&E. (C) Western blot and densitometry analysis of DHS, hypusinated EIF5A,
EIF5A2, p-Smad2 and EMT markers from primary ovarian tumors in three different mice
xenografted with DHS KO and control cells (n=3, *p <0.05;**p <0.01;***p <0.001).
Band intensity was measured using ImageJ and significance was determined by student’s
T-test.
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tumors using Western blot. Figure 4-12C showed that GC7 treatment inhibited
hypusinated EIF5A and EIF5A2 expression and downregulated the mesenchymal marker
including β-catenin, Snail2, and Vimentin and p-Smad2 expression and upregulated the
epithelial marker Cytokeratin-7 and Ecadherin. Ovary tumor sections were
immunostained with DHS, Vimentin, Cytokeratin-7 and hypusinated EIF5A antibodies,
and the results were consistent with the Western blots (Figure 4-13).

Discussion
DHS is the enzyme in the first step of hypusination and determines the activation
and maturation of EIF5A (Caraglia et al., 2013). Either KO of DHS using lentiviral
CRISPR/Cas9 nickase or inhibition of DHS with GC7 successfully blocked the
hypusination pathway in both SKOV3 and OVCAR8 cell lines (Figures 4-1 and 4-2).
The alterations of EMT markers after KO of DHS or GC7 treatment showed that
mesenchymal markers are downregulated while epithelial cell markers are upregulated in
ovarian cancer cells (Figures 4-1 and 4-2), suggesting that inhibition of EIF5A2
maturation by blocking the hypusination pathway suppresses EMT. Blocking
hypusination pathway by KO of DHS or GC7 treatment also lead to significant reduction
of cell survival, proliferation, migration, and invasion in both SKOV3 and OVCAR8
(Figures 4-3 through 4-6).
Our data show that KO of DHS or inhibition of DHS with GC7 suppressed
ovarian primary tumor growth and metastasis into other organs, such as liver and spleen,
by inhibiting EMT (Figure 4-8 through 4-13). Our findings are consistent with previous
reports that blocking DHS inhibits EMT and reduces tumor growth and metastasis in
several caner types including HCC, oral squamous cell carcinoma, breast cancer, and
bladder cancer (Zhou et al., 2017; Fang et al., 2018a; Guan et al., 2019; Yang et al.,
2014). Our results demonstrate that DHS is a potential therapeutic target for ovarian
cancer treatment. Previous studies also showed that DHS disruption by GC7 treatment
inhibits neuroblastoma cell growth (Bandino et al., 2014) and enhances the
chemosensitivity in leukemia and lung cancer (Nakanishi and Cleveland, 2016).
Therefore, targeting EIF5A2 hypusination with GC7 provides a novel approach for
ovarian cancer therapy by reversing EMT.
Interestingly, we found that KO of DHS or GC7 treatment not only inhibited
hypusinated EIF5A, but also reduced the total EIF5A2 expression in ovarian cancer cells
(Figure 4-1 and 4-2). Our finding is consistent with a previous report in breast cancer
(Guan et al., 2019) but is different from reports of hepatocellular carcinoma (HCC) and
bladder cancer (BC) (Zhou et al., 2017; Lou et al., 2013; Yang et al., 2014). GC7 only
reduced hypusinated EIF5A, but not the total EIF5A2 expression in HCC and BC. The
different effects of GC7 on EIF5A2 expression may be related to the different cancer
types.
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Figure 4-13. DHS and EMT markers were stained in sections of ovarian tumor in
GC7 and vehicle-treated mice.
(A, B, C, D) DHS and hypusinated EIF5A (green) were stained in cytoplasm, PCNA
(red) was stained in cell nuclei and Cytokeratin-7 (green) and Vimentin (green) were
stained in cell membranes from ovarian tumor sections in xenografted mice with DHS
KO and control OVCAR8-Luc2 cells. Ovarian tumor sections were also stained by H&E.
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As shown in Figure 4-11, GC7 displayed high anti-tumor efficacy as an inhibitor
of DHS in ovarian cancer and one of the most effective DHS inhibitors. GC7 has also
been shown to inhibit tumor progression in other cancer types (Zhou et al., 2017; Fang et
al., 2018a; Guan et al., 2019; Yang et al., 2014). However, GC7 has poor
pharmacokinetic and pharmacodynamic properties due to its unstable molecular structure
(Nakanishi and Cleveland, 2016). GC7 has also been reported to inhibit EIF5A1
activation (Lou et al., 2013). Since KO of EIF5A1 causes embryonic lethality and other
side-effects, further work is needed to improve the selectivity of GC7 to specifically
targeting EIF5A2 for ovarian cancer therapy.
Disruption of DHS blocks both EIF5A1 and EIF5A2 activation during the
hypusination process. In Chapter 3, our results showed that KO of EIF5A2 attenuates
Smad-dependent TGF signaling in ovarian cancer cells. In this study, inhibition of DHS
also attenuated phospho-Smad2 in both SKOV3 and OVCAR8 cells (Figure 4-7). It is
possible that inhibition of DHS attenuates the TGFβ pathway, which may be through
suppressing EIF5A activation. Further investigation is needed to determine how DHS is
involved in Smad-dependent TGF signaling pathway.
In conclusion, we reported that disruption of DHS expression using CRISPR/Cas9
nickase or GC7 blocks the hypusination pathway and leads to the inhibition of EIF5A2
and EMT in ovarian cancer cells. Disruption of DHS also leads to the inhibition of cell
proliferation, survival, migration and invasion in ovarian cancer cells, possibly through
inhibiting EIF5A2 and EMT and attenuating the TGF signaling pathway. Our results are
consistent with previous reports that found hypusination is required for the activation and
function of EIF5A2 in cancer cells and blocking hypusine synthesis using DHS inhibitors
is a novel approach for ovarian cancer therapy.
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CHAPTER 5.

DISCUSSION

The lack of early biomarkers for clinical diagnosis is a contributing factor in the
high mortality rate of ovarian cancer patients (Visintin et al., 2008). The current
screening strategy for ovarian cancer uses a combinatorial approach of transvaginal
ultrasound and blood testing for CA125, which has limited diagnostic efficacy due to
poor specificity and insensitivity (Olivier et al., 2006). Therefore, it is important to
identify an effective biomarker for early-stage diagnosis.
EIF5A2 is one of the two EIF5A isoforms and was first detected in the ovarian
cancer cell line UACC-1598 (Clement et al., 2003b). In normal tissues, EIF5A2 is only
present in testis and brain (Nishimura et al., 2012). A growing number of studies found
that EIF5A2 is highly expressed in multiple types of human cancers (Wu et al., 2020).
We analyzed 607 serous ovarian carcinomas and 561 normal tissues in the Oncomine
database and found that EIF5A2 expression is amplified and upregulated in ovarian
adenocarcinomas and is predictive of poor patient survival. These findings suggest that
EIF5A2 is a potential biomarker for early diagnosis of ovarian cancer and also a
prognostic indicator following chemotherapy.
Ovarian tumors are more metastatic than any other cancers because ovarian
cancer cells disseminate directly to other abdominal organs (Lengyel, 2010). During
cancer progression, EOC tumor cells undergo EMT and gain the motility for cancer
metastasis. Detached ovarian tumor cells dissociate into single cells or form spheroids in
the peritoneal fluid (Lengyel, 2010). We found that KO of EIF5A2 using CRISPR/Cas9
nickase inhibits EMT, while overexpression of EIF5A2 promotes EMT in ovarian cancer
cells. For the first time, we show that KO of EIF5A2 inhibits primary ovary tumor
growth and metastasis, which is consistent with previous findings that EIF5A2 promotes
EMT, metastasis, and invasion in several other human cancer types (Tang et al., 2010;
Zhu et al., 2012; Wei et al., 2014; Lin et al., 2020).
EIF5A1 is the other isoform of EIF5A and, similar to EIF5A2, is also highly
expressed in ovarian cancer where its expression promotes EMT (Zhang et al., 2018).
However, the two EIF5A isoforms have different biological functions. Homozygous
deletion of EIF5A2 in mice doesn’t affect body weight, fertility, or survival (Pällmann et
al., 2015). In contrast, homozygous deletion of EIF5A1 causes embryonic lethality in
mice (Nishimura et al., 2012). The functional similarity and difference between the two
isoforms can be explained by their crystallographic structures. EIF5A1 and EIF5A2 share
the same N-terminal domain containing the hypusination site, suggesting that the
functional similarity might be linked to the hypusine modification. However, structures
of the two isoforms differ at their C-terminal domains (Tong et al., 2009). Although
EIF5A1 and EIF5A2 compensate each other in yeast cells (Clement et al., 2003), their
functional similarity and differences in eukaryotic cells, especially in human cancers, are
still obscure. Future work should address whether KO of EIF5A2 induces EIF5A1
upregulation or activation that compensates for loss of EIF5A2 in signaling pathways in
ovarian cancer cells.
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We previously showed that the TGF pathway stimulates EMT in ovarian cancer
cells (Chen et al., 2014). The TGF pathway affects cell division, differentiation,
migration, adhesion, and death by transcriptionally regulating downstream target genes
through the Smad2/3/4 complex (Massagué et al., 2005). Possible correlations between
the TGF pathway and EIF5A2 in ovarian carcinoma cells were studied by examining
both EIF5A2 KO or overexpression cells following TGFβ treatment. We found that
TGF upregulates EIF5A2 expression in a time-dependent manner, and KO of EIF5A2
attenuates TGFβ signaling in ovarian cancer cells, suggesting a positive feedback loop
between the TGFβ pathway and EIF5A2 in ovarian cancer cells. The correlations
between EIF5A2 and the TGF pathway have been reported to be either positive or
negative depending on cancer type (Hao et al., 2020; Wei et al., 2014). Our study based
on luciferase reporter gene assays suggests that Smad2/3/4 may bind to the promoter of
EIF5A2 and activate EIF5A2 expression. To directly verify that Smad2/3/4
transcriptionally upregulates EIF5A2 in ovarian cancer cells, CHIP-PCR assays should
be performed in the future. Since hypusinated EIF5A2 is localized primarily in the
cytoplasm of ovarian cancer cells, EIF5A2 may potentially interact, either directly or
indirectly, with TGF signaling components including the TGF receptors, Smad2,
Smad3 and Smad4. Immunoprecipitation assays can be used to investigate whether
EIF5A2 directly interacts with TGF receptor or the Smad protein complex. However, it
is also possible that EIF5A2 indirectly regulates the TGF signaling pathway. In either
case, our results indicate that EIF5A2 promotes primary ovarian tumor growth and
metastasis by promoting EMT and activating the TGF pathway.
Inhibiting the hypusination pathway has been shown to suppress tumor
progression in various cancer (Nakanishi and Cleveland, 2016). However, whether
disruption of the hypusination pathway inhibits ovarian tumor growth is still unclear.
DHS has been shown to be an anti-tumor target (Bandino et al., 2014) and is required for
EIF5A maturation (Figure 1-2) (Maier et al., 2010). KO or inhibition of DHS using
CRISPR/Cas9 nickase or GC7 successfully inhibited the expressions of hypusinated
EIF5A, EIF5A2, and EMT in ovarian cancer cells. OC cell proliferation, survival,
migration, and invasion are significantly reduced following DHS KO or inhibition. For
the first time, we show that inhibition of DHS significantly suppressed EMT and ovarian
tumor growth and metastasis, consistent with previous findings that inhibition of
hypusination pathway suppresses tumor progression (Nakanishi and Cleveland, 2016).
Whether inhibition of DHS affects EIF5A2 expression is depending on different cancer
types (Zhou et al., 2017; Lou et al., 2013; Yang et al., 2014; Guan et al., 2019).
Disruption of DHS may also affect EIF5A2 protein stability. Furthermore, we show that
GC7 is an effective DHS inhibitor to block the hypusination pathway and inhibit primary
ovarian tumor growth and metastasis. GC7 may potentially affect EIF5A1 function and
thereby induce nonselective effects (Lou et al., 2013). Therefore, improvement of the
specificity of DHS inhibitors is needed in the future, in order to selectively target EIF5A2
hypusination for ovarian cancer therapy.
Blocking the hypusination of EIF5A2 in ovarian cancer cells also inhibits EMT
and attenuates the TGF signaling pathway using GC7, consistent with our findings in
DHS KO ovarian cancer cells and orthotopic ovarian cancer mouse models. KO of DHS
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disrupts primary ovarian tumor growth and metastasis by reversing EMT and attenuating
the TGFβ pathway. Our results show that targeting EIF5A2 hypusination using DHS
inhibitor is a new approach for ovarian cancer therapy.
In conclusion, this study revealed a novel mechanism underlying EIF5A2
mediated EMT in ovarian cancer progression and metastasis (Figure 5-1). Ligand TGFβ
binds to the complex of TGFβ receptor-1 and receptor-2, followed by phosphorylation of
TGFβ receptor dimers and Smads. The activated Smad complex translocates into the
nucleus where it binds to the promoter of EIF5A2 and transcriptionally regulates EIF5A2
expression. Highly expressed EIF5A2 acts in EMT regulation and promotes tumor
progression in ovarian cancer by activating the TGFβ signaling pathway. In addition, we
found that disrupting the hypusination of EIF5A inhibits the expression of both
hypusinated EIF5A and EIF5A2. Disruption of the hypusination process also inhibits
EMT and suppresses ovarian primary tumor growth and metastasis. Taken together, our
findings shed new light on potential treatment strategies of ovarian cancer and improve
our understanding of the potential mechanisms underlying EIF5A2 mediated ovarian
cancer progression.
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Figure 5-1.
metastasis.

Potential molecular mechanism underlying EIF5A2 mediated tumor
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